TouchIMMUNOLOGY got the opportunity to catch up with Dr Linda Stein Gold (Henry Ford Health System, Detroit, MI, US) around the use of roflumilast in the treatment of chronic plaque psoriasis patients (Clinical Trial Identifier: NCT04211363 & NCT04211389).
The abstract ‘Roflumilast cream, a once-daily, potent phosphodiesterase-4 inhibitor, in chronic plaque psoriasis patients: Efficacy and safety from DERMIS-1 and DERMIS-2 Phase 3 trials‘ (Presentation ID: FC01.04) was presented at the EADV Spring Symposium 2021, 6-7 May 2021.
- Could you tell us a little about the health burden and unmet needs in the topical treatment of plaque psoriasis? (0:17)
- What is the rationale for the use of roflumilast and how does it compare with the other FDA-approved PDE4 inhibitors? (1:11)
- What were the aims, design and inclusion criteria of the DERMIS-1 and DERMIS-2 studies? (1:44)
- What were the primary outcome measures of the study and how well were these achieved? (2:42)
- What other findings were there? (3:25)
Disclosures: Linda Stein Gold discloses being an investigator/advisor for Arcutis, Dermavant, Incyte, Ortho, Galderma, Abbvie, Leo, UBB, BMS.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of EADV Spring 2021 (Virtual).
Share this Video
Related Videos In Psoriasis
Andy Blauvelt, EADV 2021: Deucravacitinib vs Placebo and Apremilast in Scalp Psoriasis
touchIMMUNOLOGY had the pleasure of speaking with Dr Andy Blauvelt (Oregon Medical Research Center, Portland, OR, USA) about the oral TYK2 inhibitor, deucravacitinib, and how it compared to placebo and apremilast in the treatment of scalp psoriasis. His presentation entitled ‘Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Versus Placebo and Apremilast in Scalp […]
Leon Kircik, AAD VMX 2021: Roflumilast Foam in Scalp and Body Psoriasis
Prof. Leon Kircik (Icahn School of Medicine at Mount Sinai, New York, NY, USA) kindly took the time to speak with us about the results from the recent phase 2b study investigating roflumilast foam in the treatment of scalp and body psoriasis. His abstract entitled ‘Once-daily Roflumilast Foam 0.3% for Scalp and Body Psoriasis: A […]
Kim Papp, AAD VMX 2021: Secukinumab PURE Study
We were delighted to discuss with Dr Kim Papp (Probity Medical Research, Waterloo, ON, Canada) results from the PURE study (NCT02786186), designed to investigate the long-term safety profile of secukinumab in patients with moderate to severe chronic plaque psoriasis. The abstract ‘Secukinumab helps achieving clear/almost clear skin and improve quality of life in psoriasis over […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!